Journal of Antimicrobial Chemotherapy (2003) 51, 1-11
© 2003 The British Society for Antimicrobial Chemotherapy
Supplement |
Development of the quinolones
Bristol Centre for Antimicrobial Research and Evaluation, North Bristol NHS Trust and University of Bristol, Department of Medical Microbiology, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK
Abstract
Since their discovery in the early 1960s, the quinolone group of antibacterials has generated considerable clinical and scientific interest. Nalidixic acid, the first quinolone to be developed, was obtained as an impurity during the manufacture of quinine. Since this time, many derivatives have been synthesized and evaluated for their antibacterial potency. Two major groups of compounds have been developed from the basic molecule: quinolones and naphthyridones. Manipulations of the basic molecule, including replacing hydrogen with fluorine at position 6, substituting a diamine residue at position 7 and adding new residues at position 1 of the quinolone ring, have led to enhanced antibacterial efficacy. In general these compounds are well tolerated. However, some of these structural changes have been found to correlate with specific adverse events: the addition of fluorine or chlorine at position 8 being associated with photo-reactivity, e.g. Bay y 3118 and sparfloxacin; and the substitution of an amine or a methyl group at position 5 having a potential role in QTc prolongation, e.g. sparfloxacin and grepafloxacin. Progressive modifications in molecular configuration have resulted in improved breadth and potency of in vitro activity and pharmacokinetics. One of the most significant developments has been the improved anti-Gram-positive activity of the newer compounds, such as moxifloxacin and garenoxacin. In the current millennium, these new agents may play an important role in the treatment of respiratory infections.
Footnotes
* Corresponding author. Tel: +44-117-959-5652; Fax: +44-117-959-3154; E-mail: alasdair.macgowan{at}north-bristol.swest.nhs.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. J. Adam, N. M. Laing, C. R. King, B. Lulashnyk, D. J. Hoban, and G. G. Zhanel In Vitro Activity of Nemonoxacin, a Novel Nonfluorinated Quinolone, against 2,440 Clinical Isolates Antimicrob. Agents Chemother., November 1, 2009; 53(11): 4915 - 4920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Landersdorfer, M. Kinzig, F. F. Hennig, J. B. Bulitta, U. Holzgrabe, G. L. Drusano, F. Sorgel, and J. Gusinde Penetration of Moxifloxacin into Bone Evaluated by Monte Carlo Simulation Antimicrob. Agents Chemother., May 1, 2009; 53(5): 2074 - 2081. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Krishna, J. C. Kisicki, S. Olsen, D. M. Grasela, and Z. Wang The Effect of Omeprazole on the Bioavailability and Safety of Garenoxacin in Healthy Volunteers J. Clin. Pharmacol., May 1, 2007; 47(5): 628 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. LaPlante, M. J. Rybak, B. Tsuji, T. P. Lodise, and G. W. Kaatz Fluoroquinolone Resistance in Streptococcus pneumoniae: Area Under the Concentration-Time Curve/MIC Ratio and Resistance Development with Gatifloxacin, Gemifloxacin, Levofloxacin, and Moxifloxacin Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1315 - 1320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Griffith, T. Aksamit, B. A. Brown-Elliott, A. Catanzaro, C. Daley, F. Gordin, S. M. Holland, R. Horsburgh, G. Huitt, M. F. Iademarco, et al. An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases Am. J. Respir. Crit. Care Med., February 15, 2007; 175(4): 367 - 416. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Vassena, M. Proschan, A. S. Fauci, and P. Lusso Interleukin 7 reduces the levels of spontaneous apoptosis in CD4+ and CD8+ T cells from HIV-1-infected individuals PNAS, February 13, 2007; 104(7): 2355 - 2360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Edmiston Jr, C. J. Krepel, K. S. Kehl, G. R. Seabrook, L. B. Somberg, G. H. Almassi, T. L. Smith, T. A. Loehrl, K. R. Brown, B. D. Lewis, et al. Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients J. Antimicrob. Chemother., November 1, 2005; 56(5): 872 - 878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tachibana, M. Tanaka, Y. Masubuchi, and T. Horie ACYL GLUCURONIDATION OF FLUOROQUINOLONE ANTIBIOTICS BY THE UDP-GLUCURONOSYLTRANSFERASE 1A SUBFAMILY IN HUMAN LIVER MICROSOMES Drug Metab. Dispos., June 1, 2005; 33(6): 803 - 811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Marchetti, F. Franzetti, and A. Gori Partial immune reconstitution following highly active antiretroviral therapy: can adjuvant interleukin-2 fill the gap? J. Antimicrob. Chemother., April 1, 2005; 55(4): 401 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Trkola, H. Kuster, C. Leemann, A. Oxenius, C. Fagard, H. Furrer, M. Battegay, P. Vernazza, E. Bernasconi, R. Weber, et al. Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point Blood, September 15, 2004; 104(6): 1784 - 1792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Harnett, A. P. Fraise, J. M. Andrews, G. Jevons, N. P. Brenwald, and R. Wise Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492 J. Antimicrob. Chemother., May 1, 2004; 53(5): 783 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Grelli, G. d'Ettorre, F. Lauria, F. Montella, L. Di Traglia, M. Lichtner, V. Vullo, C. Favalli, S. Vella, B. Macchi, et al. Inverse correlation between CD8+ lymphocyte apoptosis and CD4+ cell counts during potent antiretroviral therapy in HIV patients J. Antimicrob. Chemother., March 1, 2004; 53(3): 494 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Brocavich and J. V. Etzel Introduction:Respiratory Tract Infections-- Challenges and Opportunities Journal of Pharmacy Practice, October 1, 2003; 16(5): 311 - 312. [PDF]
|
|
|
|
|
|
R. de la Rosa and M. Leal Thymic involvement in recovery of immunity among HIV-infected adults on highly active antiretroviral therapy J. Antimicrob. Chemother., August 1, 2003; 52(2): 155 - 158. [Full Text] [PDF]
|
|